BR

BrightPath Biotherapeutics Co., Ltd.

A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-21 07:30
有価証券届出書(組込方式)
Japanese ZIP 241.2 KB
2025-11-14 07:34
確認書
Japanese ZIP 8.9 KB
2025-11-14 07:34
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese ZIP 198.0 KB
2025-06-20 09:01
臨時報告書
Japanese ZIP 22.8 KB
2025-06-19 08:36
確認書
Japanese ZIP 8.9 KB
2025-06-19 08:32
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese ZIP 23.4 KB
2025-06-19 08:25
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese ZIP 933.5 KB
2024-11-08 07:35
確認書
Japanese ZIP 9.0 KB
2024-11-08 07:34
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese ZIP 224.9 KB
2024-06-21 09:07
訂正有価証券届出書(組込方式)
Japanese ZIP 254.0 KB
2024-06-21 08:34
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese ZIP 23.2 KB
2024-06-21 08:33
確認書
Japanese ZIP 9.0 KB
2024-06-21 08:32
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese ZIP 990.5 KB
2024-06-19 08:00
有価証券届出書(組込方式)
Japanese ZIP 513.9 KB
2024-02-09 07:12
確認書
Japanese ZIP 9.1 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.